SCHEMBL17084261

SCHEMBL17084261

Cc1ccccc1NC(=O)Nc1cc(Cl)cc(Cl)c1

nearest known ligand 0.69

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DDX3X O00571 3/20 0.69
DHODH Q02127 1/20 0.66
RAB9A P51151 7/20 0.65
MAPT P10636 4/20 0.65
KMT2A Q03164 3/20 0.65
MEN1 O00255 2/20 0.65
NPSR1 Q6W5P4 1/20 0.65
NPC1 O15118 5/20 0.56
HTT P42858 1/20 0.56
TRPV1 Q8NER1 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.54
POLB P06746 1/20 0.53
P2RY1 P47900 1/20 0.53
IMPDH2 P12268 1/20 0.52
ALDH1A1 P00352 1/20 0.51
HPGD P15428 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7105392 0.88 MEN1 (0.76) DHODHRAB9AMAPTKMT2AMEN1
SCHEMBL17079616 0.88 DDX3X (0.79) DDX3XRAB9AMAPTKMT2AMEN1
SCHEMBL4343434 0.84 DDX3X (0.65) DDX3XDHODHRAB9AMAPTKMT2A
SCHEMBL27568751 0.83 DDX3X (0.73) DDX3XRAB9AMAPTKMT2AMEN1
SCHEMBL1275926 0.82 RAB9A (0.75) DDX3XRAB9AMAPTKMT2AMEN1
SCHEMBL1659299 0.81 DDX3X (1.00) DDX3XRAB9AMAPTKMT2AMEN1
SCHEMBL11918074 0.81 DDX3X (1.00) DDX3XRAB9AMAPTKMT2AMEN1
SCHEMBL812756 0.81 DDX3X (0.80) DDX3XRAB9AMAPTKMT2AMEN1
SCHEMBL4350457 0.80 DDX3X (0.55) DDX3XDHODHRAB9AMAPTKMT2A
SCHEMBL11983339 0.79 DHODH (1.00) DHODHRAB9AMAPTKMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015136292-A9 USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS UNIVERSITY OF WARWICK (GB) 2022-04-21 WO disclosed
US-9884812-B2 Use of DDX3X inhibitors for the treatment of pneumovirus infections UNIVERSITY OF WARWICK (GB) 2018-02-06 US disclosed
US-20170166519-A1 USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS UNIVERSITY OF WARWICK (GB) 2017-06-15 US disclosed
WO-2015136292-A1 USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS UNIVERSITY OF WARWICK (GB) 2015-09-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166519-A1 USE OF DDX3X INHIBITORS FOR THE TREATMENT OF PNEUMOVIRUS INFECTIONS DDX3X, DDX1, DDX5 DDX3X 1/4885DHODH 819/4885RAB9A 873/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.